Application of polyethylene glycol artesunate in preparation of anti-pulmonary fibrosis medicine

A technology of polyethylene glycol artemisia annua and artesunate, which is applied in the directions of drug combinations, pharmaceutical formulations, medical preparations of inactive ingredients, etc. Ester against liver fibrosis and other issues

Inactive Publication Date: 2017-03-15
KPC PHARM INC
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Drugs that affect cytokines, such as pirfenidone and interferon, have also been used in the treatment of pulmonary fibrosis in recent year

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polyethylene glycol artesunate in preparation of anti-pulmonary fibrosis medicine
  • Application of polyethylene glycol artesunate in preparation of anti-pulmonary fibrosis medicine
  • Application of polyethylene glycol artesunate in preparation of anti-pulmonary fibrosis medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Study on the Effect of Polyethylene Glycol Artesunate on Pulmonary Fibrosis in Mice

[0027] 1. Test material

[0028] Polyethylene glycol artesunate, made by the Pharmaceutical Research Institute of Kunming Pharmaceutical Group according to the method disclosed in Example 1 of Chinese Patent CN103450468B, has a structure of formula 1; artesunate, produced by the Pharmaceutical Research Institute of Kunming Pharmaceutical Group; dexamethasone sodium phosphate Injection, produced by Kunming Pharmaceutical Group; Bleomycin (BLM for short), Nippon Kayaku Co., Ltd.; Hydroxyproline (HyP) kit, HE dye solution, Nanjing Jiancheng Biological Engineering Co., Ltd.; precision electronic balance, Beijing Sai Doris Balance Co., Ltd.; TDL-5 centrifuge, Shanghai Anting Scientific Instrument Factory; optical microscope and optical camera system, Japan OYLMPUS Company; inverted microscope, American Bio-Rad Company; ICR mice, 105, female, 18~ 22g, provided by the Experimental ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Number average molecular weightaaaaaaaaaa
Number average molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention provides application of polyethylene glycol artesunate as shown in Formula (I) in preparation of an anti-pulmonary fibrosis medicine. The polyethylene glycol artesunate can obviously reduce the degree of pulmonary fibrosis, the pulmonary index, and the content of hydroxyproline and malondialdehyde in pulmonary tissues of a pulmonary fibrosis mouse caused by bleomycin, and improve the survival, the spleen index and the thymus index of the pulmonary fibrosis mouse. Moreover, under the equivalent dose, the polyethylene glycol artesunate and artesunate are significantly different. In addition, the polyethylene glycol artesunate is high in water solubility, high in bioavailability, long in half-life period and low in administration frequency.

Description

technical field [0001] The invention relates to the technical field of artesunate derivatives, in particular to the application of polyethylene glycol artesunate in the preparation of anti-pulmonary fibrosis drugs. Background technique [0002] Pulmonary fibrosis (PF) is a disease characterized by massive fibroblast aggregation, extracellular matrix (EMC) deposition, and destruction of alveolar structures caused by inflammatory lesions and injuries, and progressive dyspnea is the main Clinical symptoms, respiratory failure at the end stage is the main cause of death. The etiology of pulmonary fibrosis is complex and can be caused by dust, radiation, allergies, viruses, drugs, etc. As a result, many patients develop diffuse pulmonary fibrosis, which seriously affects survival time and quality of life. [0003] Currently, there is no effective treatment for pulmonary fibrosis. Traditional treatment drugs include glucocorticoids, which can inhibit the chemotaxis and aggregati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/60A61K31/357A61P11/00
CPCA61K31/357
Inventor 黄照昌宋立明刘一丹朱泽李鹏辉
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap